bluebird bio, Inc.

NasdaqGS BLUE

bluebird bio, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2024

bluebird bio, Inc. Net Cash Used For Investing Activities is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Net cash used for investing activities is total cash inflows and outflows related to activities intended to generate future income and cash flows from investments.

bluebird bio, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2021 was USD 650.44 M, a 1,403.28% change year over year.
bluebird bio, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -49.91 M, a 48.30% change year over year.

Key data

Date	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure

NasdaqGS: BLUE

bluebird bio, Inc.

CEO	Mr. Andrew Obenshain
IPO Date	June 19, 2013
Location	United States
Headquarters	60 Binney Street
Employees	375
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.

Key trends

Past 5 years